Regeneron Pharmaceuticals : Antibody Cocktail Is First FDA-Approved Ebola Treatment

By Josh Beckerman

A Regeneron Pharmaceuticals Inc. antibody cocktail has become the first treatment for the Ebola virus approved by the U.S. Food and Drug Administration.

The treatment, Inmazeb, is also known as REGN-EB3. It includes atoltivimab, maftivimab and odesivimab-ebgn.

The FDA said "today's action demonstrates the FDA's ongoing commitment to responding to public health threats--both domestically and abroad--on the basis of science and data."

Regeneron shares were up 0.6% after hours at $604.62.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

10-14-20 1825ET